Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02532296 · ClinicalTrials.gov registry record · NA

Improving Hospital-to-Home Care Transitions for High-risk Younger Adult Patients

A NA study, sponsored by Cambridge Health Alliance.

Completed
Registry status
NA
Development phase
201
Enrollment target

NCT02532296: Completed NA study, sponsored by Cambridge Health Alliance.

NCT02532296 is a NA study that has completed, run by Cambridge Health Alliance. The registered enrollment target is 201 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02532296, a NA study, has completed, sponsored by Cambridge Health Alliance.

COMPLETED
Registry status
NA
Development phase
201 participants
Enrollment target

Study Summary

Improving hospital-to-home care transitions can produce improvements in patient safety and health care outcomes, while decreasing medical costs. Most transitions research has examined strategies for older patients. This project, however, focuses on younger, high-risk patients within a safety net system. The proposed intervention is based on research that patient activation, as measured by the Patient Activation Measure (PAM), is correlated with risk for hospital readmission. The intervention seeks to increase PAM scores by employing a Transition Coach to coach patients, prior to and for 30-days after discharge, to (1) improve self-management skills through goal setting and goal attainment; (2) to enhance patient capacity to engage in trusting relationships with the Primary Care Provider (PCP), other medical specialists, family members of friends, and the Transition Coach; and (3) to improve ability to navigate the medical system. The investigators will conduct a randomized trial to determine; (a) if PAM scores can be increased in the 30-day after hospital discharge; (b) if increased PAM scores, in this setting, are correlated with changes in healthcare utilization patterns; and (c) if the intervention presents a viable strategy to change healthcare utilization patterns and reduce rehospitalizations.

Primary Outcome

Comparison between pre-discharge PAM and 30-day post-discharge PAM. Hospital and ED visit and outpatient visits with PCP and Specialists at 7,14,30,60,90 days.

Interventions

  • BEHAVIORAL Control
  • BEHAVIORAL Transition Coach (TC)

Trial Details

FieldValue
Enrollment Target 201 participants
Start Date 2015-06
Est. Completion 2016-07
Phase NA
Cambridge Health Alliance

45 total trials

What the finished NCT02532296 record still lists

NCT02532296 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).

The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.

NCT02532296 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02532296 about?

NCT02532296 is a clinical study titled "Improving Hospital-to-Home Care Transitions for High-risk Younger Adult Patients". Improving hospital-to-home care transitions can produce improvements in patient safety and health care outcomes, while decreasing medical costs. Most transitions research has examined strategies for older patients. This project, however, focuses on younger, high-risk patients within a safety net sys...

What is the current status of trial NCT02532296?

This trial is currently completed. It is a NA study. The enrollment target is 201 participants. The study started on 2015-06. Estimated completion is 2016-07.

What interventions are being tested in trial NCT02532296?

The interventions under investigation include: Control (BEHAVIORAL), Transition Coach (TC) (BEHAVIORAL).

Who is sponsoring clinical trial NCT02532296?

This trial is sponsored by Cambridge Health Alliance, which has 45 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02532296's enrollment target sits among peer trials

201 506th of 2000 higher than 1,495 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04422652 · 201 participants · Phase 2

    Combination of Novel Therapies for CKD Comorbid Depression

  • NCT05327114 · 201 participants · Phase 2

    Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • NCT06099769 · 201 participants · Phase 2

    A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

  • NCT06274528 · 201 participants · Phase 2

    DORA and LP in Alzheimer's Disease Biomarkers

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02532296, the US trial registry maintained by the National Library of Medicine. NCT02532296 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.